Edit |   |
---|---|
Antigenic Specificity | CD20, Human |
Clone | LT20 |
Host Species | Mouse |
Reactive Species | human, nonhuman primate |
Isotype | IgG1κ |
Format | PE-Vio 770 conjugate |
Size | 100 tests in 200 µL |
Concentration | 1:50 |
Applications | Flow cytometry |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | CD20 Antibody, anti-human, PE-Vio® 770. The antibody recognizes the CD20 antigen, a non-glycosylated transmembrane protein of 33-37 kDa that is expressed on B lineage cells from the pre-B cell stage to the B cell lymphoblast stage. The antigen is further expressed on most malignant B cells. CD20 is not found on early B cell progenitors or plasma cells. Oligomers of CD20 form a Ca2+ channel and might function in the regulation of local responses during B cell activation. |
Immunogen | n/a |
Other Names | MS4A1, B1, Bp35, CVID5, LEU-16, MS4A2, S7, Ly-44 |
Gene, Accession # | Gene ID: 931 |
Catalog # | 130-113-375 |
Price | $365 |
Order / More Info | CD20, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Lamprecht, B. et al. (2008) Aberrant expression of the T?2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood 112 (8): 3339-3347. | Maxwell, S. A. et al. (2009) 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen. J. Biol. Chem. 284 (33): 22379-22389. | Countouriotis, T. B. et al. (2002) Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem Cells 20 (3): 215-229. | Cragg, M. S. et al. (2002) Opposing properties of CD20 mAb; in: Mason, D. et al. (eds.): Leucocyte typing VII, Oxford, Oxford University Press: . | Polyak, M. J. and Deans, J. P. (2002) CD20 Workshop Panel report: in Mason, D. et al. (eds.): Leucocyte typing VII, Oxford, Oxford University Press: . |